Pancreatic Cancer Testing Falls Short of Goals
Germline genetic testing for pancreatic ductal adenocarcinoma (PDAC) is not being fully utilized, with only 66% of patients offered testing. Significant disparities exist, particularly affecting Black and uninsured patients, who have lower odds of being offered and completing testing. The study highlights the need for improved access and targeted interventions to address these inequities.
- ▪Only 66% of patients with PDAC are offered germline genetic testing, and 69% complete it.
- ▪Black patients have 47% lower odds of being offered testing compared to White patients.
- ▪Uninsured patients have 83% lower odds of being offered testing compared to Medicare beneficiaries.
Medscape files mainly under health. We currently carry 225 of its stories.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:Germline genetic testing for pancreatic ductal adenocarcinoma (PDAC) remains incompletely implemented, with only 66% of patients offered testing and 69% completing it. Black patients, uninsured individuals, and those treated in community settings face significantly lower odds of being offered and completing testing, while only 62% of mutation-positive patients report cascade testing among first-degree relatives.METHODOLOGY:Approximately 10%-15% of patients with PDAC harbor pathogenic germline genetic alterations, most frequently in genes involved in homologous recombination repair (HRR) including BRCA1, BRCA2, PALB2, and ATM, with direct therapeutic implications for platinum-based chemotherapy and PARP inhibition.Current National Comprehensive Cancer Network and American Society…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
